From 2D to 3D Cancer Cell Models—The Enigmas of Drug Delivery Research
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Over the past decades, research has made impressive breakthroughs towards drug delivery systems, resulting in a wide range of multifunctional engineered nanoparticles with biomedical applications such as cancer therapy. Despite these significant advances, well-designed nanoparticles rarely reach the clinical stage. Promising results obtained in standard 2D cell culture systems often turn into disappointing outcomes in in vivo models. Although the overall majority of in vitro nanoparticle research is still performed on 2D monolayer cultures, more and more researchers started acknowledging the importance of using 3D cell culture systems, as better models for mimicking the in vivo tumor physiology. In this review, we provide a comprehensive overview of the 3D cancer cell models currently available. We highlight their potential as a platform for drug delivery studies and pinpoint the challenges associated with their use. We discuss in which way each 3D model mimics the in vivo tumor physiology, how they can or have been used in nanomedicine research and to what extent the results obtained so far affect the progress of nanomedicine development. It is of note that the global scientific output associated with 3D models is limited, showing that the use of these systems in nanomedicine investigation is still highly challenging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“Among them, the most known examples are Doxil® and Abraxane®, for the delivery of doxorubicin and paclitaxel, respectively [7,8].”
BackgroundModeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
The entry of nanoparticles into solid tumours
Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., et al. (2020) · Nature Materials · doi:10.1038/s41563-019-0566-2 · Cited by 1,732
Is it time to start transitioning from 2D to 3D cell culture?
Jensen, C., & Teng, Y. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00033 · Cited by 1,640
Matrigel: A complex protein mixture required for optimal growth of cell culture
Hughes, C. S., Postovit, L. M., & Lajoie, G. A. (2010) · PROTEOMICS · doi:10.1002/pmic.200900758 · Cited by 1,534 · cited 19×
“On the other hand, since Matrigel® is produced by mouse sarcoma cells, the protein composition ratio varies between batches and the biochemical and mechanical properties of the material can change.”
BackgroundInfluentialSynthetic alternatives to Matrigel
Aisenbrey, E. A., & Murphy, W. L. (2020) · Nature Reviews Materials · doi:10.1038/s41578-020-0199-8 · Cited by 1,016
Three-dimensional culture systems in cancer research: Focus on tumor spheroid model
Nath, S., & Devi, G. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.013 · Cited by 919 · cited 1×
“As a consequence, an oxygen gradient arises due to impaired O2 diffusion, which is one of the causes of necrosis in the core region [25,27,28].”
BackgroundCancer stem cells as key drivers of tumour progression
Ayob, A. Z., & Ramasamy, T. S. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0426-4 · Cited by 910 · cited 1×
“Cancer organoids (or tumoroids), recapitulate the in vivo tissue heterogeneity, including the presence of a stem cell population [118].”
BackgroundModelling cancer in microfluidic human organs-on-chips
Sontheimer-Phelps, A., Hassell, B. A., & Ingber, D. E. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0104-6 · Cited by 906
Cited by
Cybulski, P., Bravo, M., Chen, J. J.-K., Van Zundert, I., Krzyzowska, S., Taemaitree, F., Uji-i, H., Hofkens, J., Rocha, S., & Fortuni, B. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1520078 · Cited by 51
Self-citationIn Vitro Models of Biological Barriers for Nanomedical Research
Carton, F., & Malatesta, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168910 · Cited by 34
Musielak, M., Boś-Liedke, A., Piwocka, O., Kowalska, K., Markiewicz, R., Szymkowiak, B., Bakun, P., & Suchorska, W. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030862 · Cited by 18
Metadata
- Authors
- Van Zundert, I., Fortuni, B., & Rocha, S.
- Venue
- Nanomaterials
- Publisher
- MDPI AG
- Published
- 2020-11-11
- Volume
- 10
- Issue
- 11
- Pages
- 2236
- ISSN
- 2079-4991 (ISSN-L)
- OpenAlex
- W3101079494
- Cited by
- 107
- References
- 35
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From 2D to 3D Cancer Cell Models—The Enigmas of Drug Delivery Research. https://app.cochat.ai/papers/10.3390/nano10112236
- The paper
- Van Zundert, I., Fortuni, B., & Rocha, S. (2020). From 2D to 3D Cancer Cell Models—The Enigmas of Drug Delivery Research. Nanomaterials. https://doi.org/10.3390/nano10112236
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.